Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer

Sponsor
Ling-Ying Wu
Study ID
NCT04986371
Status
Unknown

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Niraparib — DRUG
    Usage following drug insert is recommended

Study Details

This is an open-label, single-arm, multi-center、non-interventional real-world study, which evaluate treatment pattern, safety and efficacy of Niraparib as first-line maintenance treatment for Chinese patient with newly diagnosed ovarian cancer , fallopian tube cancer, and primary peritoneal cancer in real world clinical practice.

Key Dates

Start date
Aug 10, 2021
Status verified
Jul 2021
Primary completion
Aug 31, 2022
Completion
Feb 28, 2025

Study Design

Enrollment
300 participants (estimated)

Primary Outcome Measure

Starting dose of Niraparib [ Time Frame: up to 3 years ]

Central Contacts

Related Studies